ESTA - Earnings call transcript Q4 2021 | Establishment Labs Holdings Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning. Welcome to Establishment Labs Fourth Quarter 2021 Earnings Call. [Operator Instructions].

As a reminder, today's call is being recorded. I will now turn the call over to Raj Denhoy, Interim Chief Financial Officer. ahead. go Please

Rajbir Denhoy

and me operator, Chief everyone, joining for Officer. Thank is thank Juan With today our Jose us. you, you, Chacon Executive Quiros,

Following your we'll our questions. prepared remarks, take

you These plans I Establishment outlook like sales. during begin, development Labs' statements call forward-looking federal financial meanings include and and based product on within will made and include securities we Before laws. this to remind These timing by are that for would forward-looking current risks management the of company's and expectations statements the and comments statements on uncertainties. management's involve

For our or factors our and cause most on Form recent a encourage other from uncertainties performance to principal results I our materially quarterly filings, on differ report affect discussion available of and which are actual these website XX-Q the review that SEC establishmentlabs.com. to risk at statements, may you

over accurate that, events to Juan March this turn it of no investigational as Motiva obligation in statements revise our clinical after contains check X, product contents from support We time-sensitive to local With a by products call any information received your exemption the United of Establishment circumstances geographies pleasure to the reminder, continually a broadcast, date reflect undertakes approved. regulatory Labs are specific undergoing our is device with only authorities is States. otherwise the to of XXXX. seek for availability. an of expand call. FDA this trial call Jose. approval required CEO, conference for and in the Labs this live the Establishment the law, which Except as The regulatory As Please to implants or or my date to update

Juan Jose Chacon Quiros

is Thank innovation into importantly, gains new we key Women's and the future. centered I share to Health -- are safe morning, continue. our and continues you, creating Most everyone our aimed for to and and markets expect be hope those the good to at healthy continues market remain everyone. Raj, gains on categories

in guidance course range guidance in of level confidence outlook the We providing geographies take a the XX% $XXX This of XXXX. markets high represents our to to full year million. year. are million for This over have contribution estimated we products new we our captures our growth XX% $XXX XXXX to of share the ability expect of and in new the over that early and existing of

where continue market market are are products healthy sold. to in our underlying and demand taking the around share see world We geographies

create share transform to confident will outlook some Raj be moment. strong we volatility, our quarter detail another in will and and markets science-based fourth continues a reconstruction. pandemic breast performance the in year expand consumer-centric aesthetics XXXX innovations that our and the for ESTA market additional on to results are for While continue. our strong provide as gains looks and XXXX

took Before It X X from of million commercialized now, million. this to years I in X like Motiva Motiva health I turn improving years deliver X the delivered we Earlier market. passed milestone recent And we Implant women's with year, several we millionth just the later, when X call crossed our significant him, over to would a journey events. our highlight to to first implants.

world women ultimate products, first as aesthetics While to Motiva, breast by to house is marketing receive proud have our them are most commercial lightly. to and needs teams journey will we we put principle this of from in Europe teams, the with in office be X embodiment leaders our who The Motiva believe accomplish which chemical of hub the efforts. by this generation benefits. their of programs the ErgonomixX us reconstruction. other guiding company with Women's unique super This offers reason, is This result founded and our the consumers, Health provides A Mia, We sales direct women to that closer will launched the initiatives all program and all our are develop direct-to-consumer and needs comfort women with their and An a understand we ever best Women's established with in program and characteristics, designed removed women believe Choice year. women our Motiva trust we This improved Joy efforts To silicones, program. location. all our improved with choosing aim can more best first-of-its-kind can Joy our terms. is them Barcelona. program Hub Establishment for their support day should developed. end, allows in we to us support changing we their they are offers we program any in and we adaptable, choose our a that so crossing look implants recently ErgonomixX one This in we XX% is these to provide the providing the the implants financial consumer are well constantly to in million European allows they what example same take selling features satisfaction. and where and as to celebrate, patient we several having also efforts and Joy greater last mechanical patient efforts Labs implants Joy implants softer trust Locating XX% accomplishment soon the from is these advocacy not latest subject on have of as properties placing the receive women. feel. making our best platform early meet tissue-like more of even as experience unique in implants well and we economic With the these around first-of-its-kind and

efforts had last Joy the will and value see are the new final an As minimally This are what to of to in we procedure. Mia of charge women realized this any into may biocompatibility Implants. first characterization is company. On of higher for not to these we this Barcelona of when markets new that interest offerings strong participating allow this early the our seeing conference the the and can translate first can achieve consumer, program, And for demonstration updated that the us submitted category our of additional surgeons commercial early into the suggest everyone our program. part established being and in hub for chemical of module we a PMA agree close augmentation geographies. by fees surgeons Motiva FDA. indication efforts to value The we like for Motiva Programs covers we and our call, that have with module we and expand launch push new the and as even further we invasive Joy

submit discussion Our in and to modular PMA submission the are We track. still ready active with second in is FDA quarter. the remain proceeding second module the on

reminder, to in a these As a aesthetic excellent track patients August passed mark, of follow-up. we the year, continue cohort with X-year and last

months. complete closed also of are in reconstruction trial and We remaining couple to revision next our the the cohort the of year, on cohort reconstruction last schedule

options improved countries. healthier available in and other mastectomy. but expander, allows this Implants our recovery. Mark MRI unique has Europe and formation women RFID-enabled months take the won We potentially surgeons a in patient into will the Motiva their an the net used progress on of SmoothSilk port, comfort our over our have differentiation London early Motiva users and including been Flora to over updates Meeting, the support provide our Flora radiation stage tissue reconstruction capsule of event imaging held launching that coming the new with Flora we artifacts the efforts Expander, Tissue help In a Flora opens features treatment belief tenders this for at official noted oncology Tissue an Adoption Breast being expander first-of-its-kind nonmagnetic, we CE Flora breast many Europe. By journey. with self-friendly already the can for will Expander and in expander. is during during marking we commercially time, encouraging, of September, additional have United our Flora States. have other which our several early and tissue launch surface, advances time Reconstruction of after understand towards also

the While the we original to to achieve which April. our can step take sharing is Motiva procedure, to more the cohort only will our we high ideals Flora offer worldwide. completed that Flora aesthetic the receive to minimally market, as we aspire On share perform these the they democratize surgeries cases reconstruction for we We reconstruction in that Mia, breast expectations enhancement reconstructive look continue breast first tracking existing future. have on recon as tools techniques with allow aesthetic Establishment forward in to well new efforts breast and in Labs the women and last invasive XXX-patient where initiative, work

We XXX% this first previously clearance of allow XXXX. breast to Mia a on According half the augmentation. system market. the are could follow-up to part our the should breast research, the belief patients, in that new had not opportunity a are in $X tools will for planned this for group considered of billion, Regulatory with ongoing this that new and that outcomes expand patients approach from the of of and our Europe and coming Motiva the continue category launch aesthetics to half support significantly have transform approximately market grow

Our make continue in clinical progress the are and regulatory ongoing, to process. commercial and efforts in we China

will cover in our the Our plan of remains XXXX. I Raj the turn financial to to launch fast-growing in over second call market results. to this Motiva half now

Rajbir Denhoy

revenue our of to for Jose. Juan growth on Reported $XX.X line range XX. $XX million, you, in January Thank in was provided million XX%. with quarter the $XX.X million the Total revenue quarter was fourth preannounced

regional the this for in a distributor Asia by single of approximately which approximately based percentage fluctuate changes quarter currency largest revenue the Latin in XX%; and levels while our made growth timing comprised XX% fourth balance. the sales sales. and quarterly reorders, XX.X% of can East our approximately total Foreign balance. which Brazil, up sales; of America inventory sales on XX% globally, changes was and From points. total, is Middle perspective, were global accounted of market Pacific Europe up made X reduced approximately Direct sales,

of well in revenue million margin gross gross was revenue XX.X% was fourth reported of onetime $XX.X mix volumes to million The compared for expenses of of same to obsolescence by the $XX.X year-ago period or in the the impacted XXXX. change geographic in to result or as certain a period a Our profit XX.X% normalized quarter year. inventory and this being return timing scrap production more as in improvements related and

and XXXX. in this congresses. million SG&A of We're prioritizing the in in down period. to Mia. from the levels in loss a loss XXXX. growth resumption research to quarter Average aforementioned quarter The disruption as SG&A Joy of other to for fourth like improved new timing due of to profit global fourth quarter to fourth the million of Our a quarter approximately net pandemic. also third operations $XX.X in in and slightly fourth as million, for practices million an prices spending the of were this million normalization meetings levels based normalized the quarter quarter Total reported million of returned business $X ago the Mia. of compared of like $XX.X medical were and ago spending clinical fourth some expenses and the quarter following from activity resulted from development will third of period from and fluctuate normalization quarter-to-quarter ago quarter $X year initiatives fourth selling investments for from the increase this primarily in year Joy period. year million quarter the again million in-person timing increased R&D fourth in of and and was fourth ago The costs quarter $X.X well the R&D million. the gross $X.X to from XXXX. expenses the operating increase expenses also increase a a the and and $XX.X initiatives the quarter trial expenses to $X.X a XX.X% saw was increased relative The quarter the approximately the same the compared in also marketing quarter Net on more $XX.X expenses. year the approximately in

previous included our at $XX.X quarter the remained compared the Campus. December of of $XX.X approximately to million position in Innovation the million strong cash used XX $X.X million in new at Our Cash Sulàyöm as of end year. investment fourth

is our replace to growth existing allow loan produce new financing and initiatives, our a This Sulàyöm allow debt terms. loan, our growth a facility to refinance capital new subject documentation, what On half the past including fund nonbinding us nondilutive improved in the would which credit us we front, to we world's will negotiation Campus term anticipate implants should facility. have larger be definitive capital with than current to The sheet signed well will the U.S. that provide Innovation our launch. more of

As guidance growth XXXX million of of in $XXX earlier, for Juan range of estimated are million, our noted $XXX providing annual XX% XX%. business. Jose to considerable to Overall, is there momentum sales we representing a

waves high taking guidance associated no will the outlook, In into pandemic. with continue, assumes the assumes range we after the continue. of factors are low and consideration, new our We share took this pressures COVID while one. refining significant expect the uncertainty globally, we end will end our current The including several

does throughout manage impact we on in XXXX situation saw range any monitor continue results contemplate addition, disruptions to chain and year. supply chain material minimal as we In this supply the We our not effectively, the our closely.

and a As commercialization expect spending drive in look number pipeline to into top and underway. to have the for development remains we the see the new our programs prioritize new P&L, to growth priority. markets continue increase we Preparing significant rest levels as of investment we future entry we down technologies of of advancing

We strong our and strong down Jose. operating the our Juan I a call However, strategic and of trend a position. back margin expenses financial turn growth to result is very revenue as company continue in sales we that, And in our increase to with over competitive percentage investments. even as gross will should believe

Juan Jose Chacon Quiros

patented significant, Motiva have Thank many for the Labs. our of of year the that for you, IRB XXX-patient Raj. for Among last foundational XXXX was growth stage a ahead Establishment years by nature study set new Innovation the year of our to at existing Robert and our strong our and the completion evidence how of the we accomplishments Mia; are: market; but the Sulàyöm our What is our the MIT us will capacity of Langer at publication that of study researchers Center already beginning group of manufacturing landmark breast are into of serve of Dr. platform among engineering the our the the reconstruction surface the scientific technologies; and program; Joy the that entry we Expander. Flora half on groundbreaking ErgonomixX current unveiling Motiva surface and the still with Tissue launch biocompatible most strong the have accomplished story. the double than biomedical global in is more provided allows launch SmoothSilk

our categories to We in within our only continue few not are space. It company But we in to grounded women's markets well-being. will next reach in transform aesthetics and more breast chapter create our in importantly, preparing our expand is reconstruction. leading solidly story, and for health our become to the next growth new the and global the over commitment and years,

our will aesthetic getting markets to closer their core journey. continue We by to women innovate in in

the China, market. the largest and United States We will world's enter

to outcomes questions. Motiva turn over will access reconstruction And worldwide We work the we new your base and Mia, now new operator category breast and up aesthetic will awareness, I a breast in breast our recon a for with opening improve to customer call the launch in aesthetics. will program.

Operator

[Operator Instructions].

Stephens. Chris with Our question is from first Cooley

Christopher Cooley

us differently bit XXXX. I've follow-up have of to XXXX, like bring the And just company differ? missionary I nuances into the Juan you quick has pipeline required, approach this commercialization, only women patient, the year to of marketing on how market, could the they're commercialization going a about in more doing operating market to Mia. think from to but these perspective, you of upon us would little new in stages not in year of may, also what this interact super a message then is Europe a with how set skill that say, on expenses. opportunity kind to surgeon the in help to terms Motiva here sale, with will, we this I and got the how type if of this And start, as should I Congratulations Jose, on early if focus

Juan Jose Chacon Quiros

exciting Thank breast happy one And is landscape most one of we of you, Chris. the is be transformation And the happening things important aesthetics definitely, to with Motiva in you things most aesthetics. just leading this is are Mia mentioned. the in Motiva And Mia. that of had what

different important Hub most does customer base opening done a of traditional funnel a that not the lot new Women's able to in one We customer bring of are the be requires we the of Health is our that that Europe. It's what new breast I internal have in things capabilities customers. creates in patients. bringing and augmentation And that to interactions. those it lately is think to new And create base

we is that to having deliver clearly be not And because going promise. very will creating customer on able firepower defined we watching but the that make our that acquisition So a funnel only effective have in Barcelona awareness, be needed very to very costs think now to we carefully. this is

standardized On actually, several to promise. to much year, surgeons remember comes of And for the has than that surgeon it tools, procedure. a surgery Mia out It on is makes traditional one it other is it during on when the these simpler easier augmentation. lot last so found things hand, do education, the we a to deliver we standardized breast It's the how trained procedure. actually surgeons it the

a in few Europe education continue we for course, the of take which have clinics, efforts expand plan it our are all the so we time. prepared cities targeted then only the trained surgeons not that place in to half surgeon as will year, will on first So launch, to of the And we we year. second to in necessary expand of this half in the more

Christopher Cooley

transformational XX% Raj, organic But vein, then if the top same along as of year off Understood. is so least, in just just hopefully you impressive follow-up. the kind Labs my of in as of XX% for line truly I launch the at could, year, U.S. Motiva take to a growth comp in provided continuing And the share. XX% Mia, for this a 'XX. in to -- kind for our guidance China, and perspective Motiva Establishment well with

think us just different of a help maybe So a when may could OpEx years, maybe perspective? second prior half, versus little spend about this timing from thinking little bit expenditures, be the you we're a how first half bit planned kind about of total

Rajbir Denhoy

Yes, sure. Yes, it's Chris. good to to talk you,

Your one. Certainly, percentage the we're prepared noted what describing, But of investments. right, we the we revenue trend of our question good even new launch doing that remarks, was is over Juan ongoing, Joy, the as do expenses with they a Mia, expect as in this initiatives year. of strong as top our lot in require will a we Jose growth, given do a time and down operating line have

to year the a you on. trust will of you'll of the a that terms be timing committing are certainly, at very spending look efficient in see mindful the to what tight very level. in bit we're should will But very And first do as about lower these we little expenses we're build going we this way. judicious of and at goes part things. on. them we're we're the I And the year, would of In expect, when a expenses, our expenses

Operator

Our is next Jefferies. Wayne from question with Zack

Unidentified Analyst

terms years what like coming historically, on you talk a year. or the X I launch to commercial just another the there? know in end market X, $XXX this sized launch Can I the share just Can China. just wanted Congrats -- you quarter. you talk launch? about strategy of focus million, post the on maybe of at $XXX successful looks And million. good

Juan Jose Chacon Quiros

aesthetics our in Thank the selling is And because is Motiva average are world. It market the it with prices we about the world. you, excited very into the the one in Zack. fastest-growing highest coming one with China of breast Implants

Korean of kind one how our a fast South that talk the to to success So And seek in exploit. things us and often And is to combination that that instance. Asia we the of leadership South take is we in one market we position the happens defines Korean China. in what about they Korea, were And training and Chinese for before XX% same trends, Korea doing surgeons. South the in plastic pandemic, of plastic of follow market the the surgeons Motiva came most from the the Chinese the because about are patients medical for South for

how So China. we have very can of we good points some in already do reference well

We a in good in strategies with at have very a been partner our similar China. Korea, that our set use using plan And South partner. is strategy and strategy direct-to-market, we has to direct-to-consumer

end reality. We be working make are with able by for a we to partner year, launch the planning of to and that the our are a

Operator

with Our is Jennings Josh next question from Cowen.

Joshua Jennings

want the smooth first XXXX for been It's implants their pulling to start just Allergan on AbbVie months and anniversary of XX about I markets. or thinking global now. most

into a share And Langer every different feel establishing is, positioned you do is in or is XXXX, that paper the out I a report, but Motiva have there. share, position all just market, that You country with know a table? jump assumption even guys one higher all that of Allergan baked And the capture that provided? jump in the the you part share now of that strong left is percentage -- guidance assumption is baked on to

Juan Jose Chacon Quiros

pulled that the Allergan outside texture Yes, world States, United mostly when implants market. market the their I of that was a think from

from in results medical mentor since And education those then able to the of And our of in ramp QX, done is implants many where implants. is pullout can with instance, to see extremely something customers use do. that our teach textured first efforts medical went well to education on at that continuing following continue a So we of surgeons in market. have for doing how we've our the to what we been Brazil, you brand. to generation the to plastic another terms this be of

these think, use continue of opportunity Motiva also Implants. how teach to market that but we we to market that's course, Brazil, continue gain of share on And in most use we all to is why does all accounts about to over talking share gain an So just new as the taking and share importantly, that more think initiatives. I real we the year. expansion is Josh, market go keep during market to world. this XXXX more from And something But I will what that we

Joshua Jennings

Excellent.

follow-up XXXX Just our headwind just just XX% on XX% what Actually, headwind mean quickly the on is have to I guidance, again. of about, XXXX. that one you're XX%? But talk presumption. that follow-up that into to baked can on XX% I is inclusive one that, currency Raj, -- that you just absorbing XXXX. within And

Rajbir Denhoy

we Sure. assumed of look because currency to point Yes. about in numbers. absorbing X year, the last for the average we've When rates year headwind percentage currency a at XXXX those relative this we're rates

Joshua Jennings

Great. think into just and the play. moving And U.S. I thinking launch XXXX, going launch as to about then be we're in China potentially XXXX,

front to for launch, launch front we the U.S. rollout now attacking base? plastic launch faring for there's post through prepare to setting wanted the limited in experienced and we've and ask launch? customer wanted Just about force metal? just you Or of launches then it's And an U.S. Flora regional Europe early and that see the members of approval? get a Europe, can seen expectations should to in pedal compared have assumption front getting really place to the expectation surgeon sales Mia some the time the in approval, in kind going work the to whether stage the How in how and in in to buildup of of and thinking our you how take some launch you sales limited can about the be you and as go of just

Juan Jose Chacon Quiros

comes of the of by this reasons not we sales U.S. have course, We fundamental in for for a begun of it in both already terms be MSLs in Yes. When and that preparing judicious the we'll it necessary, of Operations. company affects do U.S. is U.S. the of one and is for of be course, doing success launch. Heather Commercial that comes this very our reps hired company And logistics what to public. Head to our Dr. infrastructure personnel, type up launch. levels way other systems hiring our setting and this milestone it took is creating spending We're ourselves to Brennan to the and When launch, of ahead market. able a in be the necessary to we

Operator

Matt is Taylor UBS. next question Our with from

Matthew Taylor

The the Or those first materiality I there a just a year launches, ask year. material to this just of new one gradual Is baked some Flora, revenues assumed? XXXX? ramp China on those talk Could of of and more this the in was you the are transition wanted of how revenue about Mia, guidance? into products product lot of is kind a

Juan Jose Chacon Quiros

Yes.

basically last done a in time. takes And of process in I tender the when more is transition. the to it's there launched think Europe. gradual comes Because different second that growth of through half year, we regions and it breast reconstruction, in the

take years. or centers only every X these year place Sometimes once a

launched. to it So of And that. comes the basically growth is Joy, already when because gradual we

at for the making current sure -- significant are the premium program We the are right. products Implant. these from Remember, Ergonomix sold we a that get

premium these to want these sure of prove to on new I train surgeons take to the patients defend of we by want the are. year can Mia, that the implants a So and and we place more that benefits practices. And to communicate able that benefits it's think features what be to and those bringing expansion patients with of finally, also making

initiatives. that's sure see it those make that get going you guidance, all what And of in to we is right. we're So that growth why new a gradual

Matthew Taylor

had line us reasonable half FDA guess could holds, you do time in on Maybe I maybe get first submit to lines. the And with I want time heard you a assume of about And the the you you've so up Is that to that Great. give follow XXXX back second just about could the Great. then talk just module from to U.S. you're quarter. insights with said prepared if it second the ready any forth and quarter. approval? far? best in of when question the remarks,

Juan Jose Chacon Quiros

the to the That change, to when timing and submit review be we is continue FDA prepared to ready could module it.

a we But situation, move they to right time the it continue be to So it's any line, the terms just to difficult is that FDA now. of give forward. information endorsing in absolute fluid process to But do ready continue right? to to an need allow

Operator

BTIG. next question is with from Our Marie Thibault

Marie Thibault

to drill bit -- wanted geographies the a little down more I try into to you've

Rajbir Denhoy

been competitive continued for this Latin of and do some frankly region good very a changes America the as That's in driven to that market. has year. a us by Brazil lot

So the a But standout And year. in growth we share. if has of was markets Brazil. this continue pretty it the numbers, to certainly, overall. particular, generally, I in one most compete year you on you in out been wanted saw call But would us as much and good to we that take a Brazil terms focus for of

Marie Thibault

market? And That's we that from that's impact great. should Russia, expect key any a thought

Rajbir Denhoy

into everybody hope do markets course, to And as a is, the what's Ukraine. and we Russia We we're closely and smaller sell and happening They watching of there. are resolution quick situation for for us. peaceful there

are of I an it's really I low our tell would out significant. small, low, going you, revenue, as call markets think digits. relatively overall sort it's too whether those of to single But piece early to be

Marie Thibault

you could you centers that the might launch. within I if the you're be Barcelona If more expecting little area whether here of thinking with focus and around granular understood. or be lot any get wondered to Mia, well Very call bit countries you of might a whether out another particular how launch on many Okay. ask that start training early about with a in can I sort happening could the and

Juan Jose Chacon Quiros

Marie. you, Thank

of the how to measure and cities We us, well us. to the very, can the you, Mia. this I Union. in for that can is we're are in the to providing going make to we And market sure list the one. is about this can to hub very prove the tell capabilities important say able European we important What be is countries defining the of to But launch expand that market. is as most I these still expansion that cities And capabilities can

that we do about procedure cities that the fact minutes efficient, more expansion numbers to place. be Europe. of do this surgeon less a and more to then the in expect and And flow main to of to many we don't numbers expand help in that that patients to this you can in centers revenue. after can set this you do talking are first we to us takes get But meaningful XX think if gradually. than about going understand need a how a is so market that able really And that you see are do You'll the phase,

Of that most grow we next think continue is But course, things. to the years. few one over will I important of the

revenue You don't of centers to milestones. thousands able and be our to reach need thousands

Operator

from is Sachs. Amit question Hazan Goldman with next Our

Philip Coover

questions been This I if is Phil follow-up items, could, asked. A of on for that from Amit. have couple already

just so on The a combined first for said one and on Ukraine the was just the sales? have single now, impact? of And potential comment low as that idea Raj. a basis, we sizing I that negative Russia, you is total an digits percentage think

Rajbir Denhoy

It's low, low single Yes. digits.

I So the basis of them. that single-digit on a X between And kind numbers. combined of is think

Philip Coover

percentage of sales? On total a

Rajbir Denhoy

exactly. Yes,

Philip Coover

Okay.

Okay. That's clear. follow-up question. One Matt's item on

in the call. XQ think went I module first before just the

establishment I last over FDA years, everything to in fair lines doing log a FDA bit that on of kind just the if far timely with. so say? in instances, having time to kind of end? their the math of we're I on want jam it's department couple concerning, I have you're fashion we've So depending it number of is just a right, on clarify the past is then which just Is that my of to pushed would basically a that Is assume, and traditional already what been nothing window. XX-day out fair think based dealing heard say is

Rajbir Denhoy

Yes, right? lot think to the gets FDA, them. a lines, assumption. clearly, right? there's about on, so a So I I remains mean that's dialogue and question endorsing the the And active earlier -- time it with fair going

FDA you the things with expectation that's take with disrupting they that will need is time. next quarter, based things -- that But -- And it's not would our submit we're as call anything the how line, noted, the is that that I information So the our we or we're progressing. noted, seeing really upon -- providing right? second out them we're again, module we're the As I interaction nothing just concerning as and time in these it. is

the want So this in up gets held that progressing. it party be we to reason any don't or terms of

Philip Coover

Very clear.

Rica one of facility submission? be conjunction between -- the third out? to and from going capacity in module, the the completion think your play submission if Is there does new facility? that the with a Costa is around I Or -- there more, given any to third manufacturing implication potential Just may. how U.S., module, relationship the of that's completion I that interested I facility that was typically, in if any third the coming

Rajbir Denhoy

Yes. linked at No, all. they're not

So will no the FDA. bearing the timing that's facility under on have new with construction the

Operator

back Thank Juan now will you. remarks. the closing over this Jose time, and more There at are questions no turn to for I call

Juan Jose Chacon Quiros

forward today's and health. call. good providing update wish in peace for everyone Thank continued Ukraine. prayers And to we quarterly you We for joining look on us in May, our offer we next our

Operator

concludes you. today's This Thank conference.

may you Thank disconnect for lines. your participation. You your now

Juan Jose Chacon Quiros

operator. Okay. Peter. Thank you, Thank you,

You're still there. guess not. I

Okay.

Establishment Labs (ESTA) 1 Mar 222021 Q4 Earnings call transcript